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Summary The association between Ki-ras mutations and proliferation activity was investigated in a
comprehensive series of biliary tract carcinomas (BTCs). We precisely microdissected samples of tissue from
paraffin-embedded sections of 77 BTCs including 22 intrahepatic cholangiocarcinomas (ICCs), 36 extrahepatic
cholangiocarcinomas (ECCs), and 19 gall bladder carcinomas (GBCs). Ki-ras mutations at exons 1 and 2 were
determined by the polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) method
and confirmed by direct sequencing. Proliferation activity was immunohistochemically assessed to generate
proliferating cell nuclear antigen labelling indices (PCNA LIs). Ki-ras mutations were detected in 10 of22 ICCs
(45%), 24 of 36 ECCs (67%), and in 16 of 19 GBCs (84%). The frequency of Ki-ras mutations in peripheral
type ICCs was 33% (4 of 12) and that in the hilar type ICCs was 60% (6 of 10). In ECCs the highest value of
82% (9 of 11) was found for carcinomas located in the lower part of the biliary tree. Mean PCNA LI in
mutation-positive BTCs was significantly elevated compared with the mutation-negative value. These results
indicate frequent involvement of Ki-ras mutations in BTCs, especially in GBCs and in distal ECCs, and that
carcinomas harbouring a mutation feature high cell proliferation activity.
Keywords: biliary tract carcinoma; Ki-ras gene; proliferating cell nuclear antigen; cholangiocarcinogenesis;
polymerase chain reaction-single strand conformation polymorphism
In the last decade, the significance of alterations of oncogenes
or tumour-suppressor genes has become a paradigm in cancer
research. It is now generally accepted that accumulation of
damage to critical regulatory genes in a multistep manner is
the essential mechanism of human tumour pathogenesis
(Marx, 1989; Fearon et al., 1990). Recent investigations of
suppressor gene transfection or blocking the function of
mutated oncogenes have provided strong support for this
conclusion and offer clues to new anti-cancer treatment
approaches (Krzyzoiak et al., 1992; Sumi et al., 1992;
Shirasawa et al., 1993; Fujiwara et al., 1994). For example,
abrogating the mutated-ras-mediated pathway which exerts
transforming activity has been reported to be effective for
growth inhibition, at least in in vitro models.
Biliary tract carcinomas (BTCs) are characterised by a
poor prognosis, because of difficulties in early detection and
radical surgical removal as well as being refractory to chemo-
and radiotherapy (Boerma, 1990; Ohashi et al., 1994a). Basic
information on gene alterations is therefore required to
understand the mechanisms of their pathogenesis and to
facilitate development of genetic approaches to therapy. In
terms of gene target therapy, mutated-ras has been
considered as a candidate from several reports of experi-
mental therapy, describing disruption of the Ki-ras gene or
depletion of farnesyl isoprenoid to inhibit mutated-ras-
mediated cell growth (Krzyzoiak et al., 1992; Sumi et al.,
1992; Shirasawa et al., 1993). Thus, an accurate estimation of
the frequency of association between Ki-ras gene mutations
and BTCs is important.
The reported frequencies of Ki-ras mutations in BTC have
varied greatly (Almoguera et al., 1988; Tada et al., 1990;
Capella et al., 1991; Levi et al., 1991; Motojima et al., 1991;
Stork et al., 1991; Tsuda et al., 1993; Imai et al., 1994) and
the discrepancies require explanation. In most cases, whole
materials from sectioned formalin-fixed paraffin-embedded
specimens of fresh frozen tissues were used for DNA
extraction. The possibility of contamination with quantities
of DNA from the interstitial tissue which is prominent in
BTCs must be taken into account. We previously reported
consistently high frequencies of Ki-ras gene mutations in
both intrahepatic cholangiocarcinomas (ICCs) and extrahe-
patic cholangiocarcinomas (ECCs) using DNA samples
extracted from microdissected tissues under the light
microscope (Ohashi et al., 1994b). This approach allows the
nature of the sampled cell population to be assessed more
accurately.
In the present investigation, we extended our previous
studies and estimated the mutation rates of a large series of
accumulated BTC cases including gall bladder carcinomas
(GBCs). In addition, the study included an evaluation of the
possible correlation between Ki-ras mutation and prolifera-
tion activity of tumour cells as determined by proliferating
cell nuclear antigen (PCNA) staining, since an understanding
of proliferation activity of the tumour cells is very important
to provide evidence of biological malignancy (Kitamoto et
al., 1993; Ohashi et al., 1994a). PCNA, a nuclear auxiliary
protein for DNA polymerase-6 which is closely linked to the
cell cycle, is now generally recognised as a useful marker for
detecting proliferating cells (Bravo et al., 1987).
Materials and methods
Tumour materials
Formalin-fixed, paraffin-embedded tissue material from 77
BTC patients in the pathological archives of Nara Medical
University and its satellite hospitals was used for the analysis.
The tumours comprised 22 ICCs, 36 ECCs and 19 GBCs.
The specimens were obtained at surgical treatment between
1982 and 1994. In all cases the location and origin of the
tumours could be confirmed by clinical and pathological
examinations and pancreatic or papilla Vater carcinomas
were not included. ICCs were divided into two groups and
ECCs into three groups depending on the location of the
tumour origin. According to the classification of Okuda et al.
(1977), a peripheral ICC (n = 12) is defined as a tumour
originating from the bile duct peripheral to the second fork
and a hilar ICC (n = 10) is one originating from the bile duct
between the second fork and the hepatic hilus. Proximal
(n = 17), middle (n =8) and distal (n = 11) ECCs are defined as
tumours originating from the bile duct between the hepatic
hilus and the cystic duct junction, the cystic duct junction
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April 1996and the upper margin of the pancreas, and the upper margin
of the pancreas and the ampullar region respectively. To
eliminate bias in interpretation of gene alterations, the
divisions of ICCs and ECCs were performed by surgeons
and pathologists without knowledge of the results of the gene
alterations by unanimous consent.
DNA extraction and amplification
A microdissection method was used for tissue harvesting as
previously described (Tsutsumi et al., 1993b; Yanagisawa et
al., 1993; Ohashi et al., 1994). Briefly, serial sections 4- and
20-im thick were cut and attached to slide glasses. The 4 ,um
sections were stained with haematoxylin and eosin (H&E) to
confirm the presence of carcinoma tissues. The 20-am
sections were stained with haematoxylin after deparaffinisa-
tion. With comparative microscopic observation of the H&E
stained section for orientation, tumour cells were cut out
using 23-G syringe needles, excluding mesenchymal cells as
far as possible. As a countermeasure against heterogeneity
within single tumours, ten parts in each case were arbitrarily
selected from peripheral and central regions and approxi-
mately 1000 cells per case were harvested. These samples were
cleaned with ethanol, completely dried and incubated in
400 ml of lysis buffer [10 mM Tris-HCl (pH 8.3), 50 mM
potassium chloride, 2.5 mM magnesium chloride, 0.45%
Tween 20) containing proteinase K (0.5 mg ml-1) for 48 h
at 55°C following the protocol described by Wright and
Manos (1990). A 159-bp fragment of the first exon of the Ki-
ras gene was amplified by polymerase chain reaction (PCR)
using the primers: GGAATTCGACTGAATATAAACTTG
a \
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TGG and GGAATTCCTGCACCAGTAATATGC. To
target codon 61 of Ki-ras, which belongs to exon 2, the
following primers yielding a 116 base pair were used:
GGAATTCCTACAGGAAGCAAGTAG and GGAATTC-
CTCATGTACTGGTCCCT. After denaturation for 3 min at
95°C 500 ng DNAs or distilled water without DNA as an
internal control were allowed to run for 60 s at 92°C, 120 s at
55°C and 120 s at 72°C for 40 cycles.
SSCP and sequencing analysis
The PCR products of 159 and 116 bp were analysed by single
strand conformation polymorphism (SSCP). Five per cent
polyacrylamide gels containing 45 mM Tris-borate (pH 8.3),
4 mM EDTA, and 10% glycerol were prepared, and gel
electrophoresis performed at 30W for about 4 h both at 5°C
and 30°C constant (LKB Macrophore DNA electrophoresis
system, Pharmacia Co, Ltd., Sweden). Gels were dried and
exposed to radiographic film at -80°C for about 2 days.
To determine nucleotide sequence alterations detected by
mobility shifts in PCR-SSCP analysis, we sequenced the
DNAs after their amplification by asymmetric PCR
(Gyllensten et al., 1988). DNA fragments showing a mobility
shift compared with the normal control by PCR-SSCP
analysis were separated and eluted from the polyacrylamide
gel according to the method of Suzuki et al. (1991). After
subsequent PCR using the same primers as described above,
amplification reaction mixtures were purified with a
Microcon (Amicon, Denvers, MA, USA). For determination
of nucleotide sequences, the dideoxy chain-termination
method (Sanger et al., 1992) was performed using a dsDNA
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Figure 1 PCR-SSCP analysis of the Ki-ras gene in biliary tract carcinomas (exon 1). (a) Representative SSCP results of 22 cases.
Fragments with abnormal mobility shifts are evident in cases 1, 3, 4, 6, 7, 9, 11, 13, 15, 18, 19, 21 and 22 (arrowheads). IC, internal
control without adding DNA. (b) Representative direct sequencing results around codon 12 ofthe Ki-ras gene ofcontrol, cases 1, 3,
4 and 9. Cases 1 and 4 demonstrate G to A transitions in the second position (arrowhead). Cases 4 and a G to T transversion in the
second position (arrowhead). The sequencing results of cases 6, 7, 11, 13, 19, 21 and 22 were the same as for cases 1 and 4 and the
results of cases 9, 15 and 18 were the same as for case 3 (figures not shown).
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cycle sequencing system (GIBCO BRL, Gaithersburg, MD,
USA) and products were analysed in 6% polyacrylamide gels
containing 7 M urea. Gels were dried and exposed to
radiographic film at -80°C for 2 days.
PCNA immunohistochemistry and scoring
Serial 4-,um sections were stained for PCNA using the avidin-
biotin complex immunoperoxidase technique (Hsu et al.,
1981). After deparaffinisation, the sections were incubated
with mouse monoclonal antibody against human PCNA,
obtained from Dakopatts (Copenhagen, Denmark), at a
dilution of 1:100 for 1 h at room temperature. Between
incubations, sections were washed extensively with Tris-buffer
saline (pH 7.6). Sections were developed using 3,3'-diamino-
benzine tetrahydrochloride and hydrogen peroxide in 0.1 M
Tris buffer, pH 7.6. Cells were considered positive for PCNA
when reddish-brown staining limited to the nucleus could be
identified. In each case the PCNA labelling index (LI) was
determined by counting 1000 cancer cells in total from 10
parts which were adjoining the areas harvested for gene
investigation in serial sections and expressed as the
percentage of positive nuclei.
Statistical analysis
The PCNA LI results were used to calculate mean+s.d.
values. Intergroup comparisons of the PCNA LI were carried
out using Student's t-test. The x2 test was applied to test the
hypothesis that the frequency of Ki-ras gene mutations is
equal in BTCs regardless of tumour location. A probability
value P<0.05 was considered statistically significant
Results
Ki-ras gene mutations in bile duct carcinomas
Representative results for Ki-ras mutations assessed by
PCR-SSCP followed by direct sequencing are shown in
Figure 1. The reproducibility of the method was confirmed by
reanalysis for all cases. Control omitting DNA did not show
any bands excluding the possibility of artifacts in this
experiment. Mobility-shifted bands suggesting gene muta-
tions were detected in 50 of the 77 tumours (65%). In all
samples with an abnormally shifted band, point mutations
could be demonstrated in the second position of codon 12 by
direct sequencing (Table I). The tumours involved were 10 of
the 22 ICCs (45%), 24 of the 36 ECCs (67%), and 16 of the
19 GBCs (84%). The frequency of Ki-ras mutation in BTCs
according to their location is shown schematically in Figure
2. The Ki-ras mutation rates tended to increase for BTCs as
the tumour location neared the lower end of the biliary tract
(peripheral ICC vs distal ECC; P<0.05). The most frequent
mutations were G to A transitions (45 of the 50 mutated
cases) resulting in a Gly to Asp amino acid substitution. The
remaining five cases with mutations demonstrated G to T
transversions, which represents a Gly to Val amino acid
substitution. No mutations in codon 13, 61 or the other
positions of codon 12 were found.
PCNA LI in bile duct carcinomas
Data for Ki-ras mutations and PCNA labelling indices in
BTCs are shown in Table II. The mean PCNA LI values
were higher in Ki-ras mutation-positive ICCs, ECCs and
GBCs than in their mutation-negative counterparts, although
Table I Spectrum of Ki-ras gene mutations in biliary tract carcinomas
Ki-ras mutation
No. ofpositive/ Sequence changes No. of
tested in codon 12 cases
Intrahepatic cholangiocarcinoma 10/22 (45) GGT (Gly) to GAT (Asp) 8
GGT (Gly) to GTT (Val) 2
Extrahepatic cholangiocarcinoma 24/36 (67) GGT (Gly) to GAT (Asp) 21
GGT (Gly) to GTT (Val) 3
Gall bladder carcinoma 16/19 (84) GGT (Gly) to GAT (Asp) 16
Numbers in parenthesis are percentages.
Tumour Ki-ras mutation
location (no. positive/
no. tested)
Peripheral ICC 4/12 (33%)
Hilar ICC 5/9 (56%)
Tumour Ki-ras mutation
location (no. positive/
no. tested) Proximal ECC 9/17 (53%)
Middle ECC 6/8 (75%)
Distal ECC 9/11 (82%)
Figure 2 Schematic illustration of tumour location and the frequencies of Ki-ras mutations in biliary tract carcinomas. Note the
high frequencies of mutation in GBC and the lower part (middle and distal) ECCs in the series of BTC. Significant differences in
frequencies were found between peripheral ICCs and distal ECCs, peripheral ICCs and GBCs, and proximal ECCs and GBCs.Table II Ki-ras mutations and PCNA labelling indices (LIs) in
biliary tract carcinomas
Ki-ras muta- No. of cases PCNA LI
tion
Intrahepatic + 10 51.4+ 10.4
cholangiocarcinoma 12 40.2 17.8
Extrahepatic + 24 50.5 i 12.9
cholangiocarcinoma 12 42.2 ± 15.7
Gall bladder + 16 46.8+14.0
carcinoma 3 42.9 ± 22.9
Combined + 50 49.4+ 12.81 *
27 41.4+ 16.4]
PCNA, proliferating cell nuclear antigen. Values are mean+s.d.
*P<0.05.
without statistical significance. When the three carcinomas
were combined, the mean PCNA LI in Ki-ras mutation-
positive cases was significantly elevated compared with
mutation-negative cases (P <0.05).
Discussion
The present observations with a large series of tumours
clearly demonstrated frequent involvement of Ki-ras muta-
tions in BTCs, especially in gall bladder and lower bile duct
cases. Furthermore, the mutation-harbouring cases demon-
strated a significantly higher proliferation activity of the
tumour cells than the mutation-negative cases.
It is well recognised that ras gene activation, mostly
induced by point mutation, is strongly associated with
carcinogenesis. In BTCs, the frequencies reported so far
have varied greatly, ranging from 0 to 58% in ICCs (Tada et
al., 1990; Tsuda et al., 1993), 8 to 100% in ECCs (Capella et
al., 1991; Levi et al., 1991; Motojima et al., 1991; Stork et al.,
1991; Imai et al., 1994) and 0 to 39% in GBCs (Almoguera et
al., 1988; Capella et al., 1991; Tada et al., 1990; Imai et al.,
1994). The discrepancies in mutation rates might be
accounted for by the different methodologies applied for
DNA extraction as well as the small numbers of patients
examined in each report. Since BTCs are often rich in
interstitial tissues, it is conceivable that contamination with
non-tumour cell DNA might mask mutations of tumour cells,
resulting in low frequencies of positives when fresh frozen
tissue or whole tissues of paraffin-embedded material are
used. It has been reported that at least 5-10% cancer cells
are needed for detection of gene mutations before amplifica-
tion for PCR (Burmer et al., 1989). In this context, the
microdissection method is important since we can ensure
more than 10% cancer cells even for such interstitial-rich
tumours as BTCs. Our previous study showed microdissec-
tion and PCR-SSCP analysis to be a reliable method
(Ohashi et al., 1994b) and the results were confirmed in the
present investigation of a larger series of accumulated cases.
One of the interesting findings in the present study is that
the mutation rates differed significantly with the tumour
location. The mutation rates were higher in GBCs and distal
ECCs compared with other BTCs. Hepatic metabolism of
carcinogens leads to the production of mutagenic intermedi-
ates which are excreted into bile in the biliary ductules and
are collected and concentrated as they pass progressively into
intrahepatic and extrahepatic ducts and finally the gall
bladder, where one would expect to find the highest
concentration of mutagens. These agents are also known to
exert a promoting action for cholangiocarcinogenesis
(Makino et al., 1985). Therefore, it is reasonable to speculate
that one of the major contributory factors for the differences
in mutation rates could be the differences in the concentra-
tion of excreted mutagenic intermediates and/or differences in
their composition at different sites within the biliary tree.
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Nitrosamines such as N-nitrosobis(2-hydropropyl)amine or
N-nitrosobis(2-oxopropyl)amine are known to induce not
only pancreatic carcinomas but also bile duct carcinomas
which harboured mutations in the Ki-ras gene in animal
models (Tsutsumi et al., 1993a and b). These agents produce
primarily methyl adducts at the N7 and o6 position of
guanine (Lawson et al., 1981; Kokkinakis et al., 1989). The
guanine in the second position of Ki-ras codon 12 (GGT)
may be sensitive to mutation owing to flanking nucleotide
residues, thus GGT to GAT or to GTT alterations occur
(Cerny et al., 1992; Tsutsumi et al., 1993) as also found in the
present study. Moreover, differences in susceptibility of
different organs to such DNA alterations by these chemicals
may play a causative role (Tsutsumi et al., 1993a). We
previously reported a higher frequency of Ki-ras mutations in
pancreatic carcinomas than in cholangiocarcinomas induced
by the same carcinogen using the hamster animal model.
Thus, another hypothetical interpretation is that susceptibility
to DNA damage of epithelial cells varies in accordance with
the location in the biliary tree.
As a further possible factor influencing mutations in
BTC, especially of significance for GBC, anomalous
arrangement of the pancreaticobiliary ductal system (APB),
which permits reflux of pancreatic juice into the biliary
system has been recognised (Komi et al., 1989). The
interaction of pancreatic juice with bile has been reported
to play a key role in cholangiocarcinogenesis (Qian et al.,
1993). Ohta et al. (1993) reported that biliary papillomatosis
occurring in the bile duct with APB features Ki-ras
mutations. APB was a feature of two of the ECC cases in
the present study, and these two cases both demonstrated
Ki-ras mutations. From these findings, it is reasonable to
assume that involvement of Ki-ras mutations during
cholangiocarcinogenesis might, in part, be affected by the
degree of pancreatic fluid reflux and its concomitant
interaction with bile, thus resulting in a very high
frequencies of mutation in both distal ECC and GBC.
The narrow spectrum of mutation (GGT to GAT or GTT)
in BTCs is noteworthy compared with other types of
malignancies such as pancreatic or colon cancer (Forrester
et al., 1987; Mariyama et al., 1989; Scarpa et al., 1994). The
method used in the present study for detecting mutation is
well established and is generally considered reliable for
detecting mutations (Orita et al., 1989), so a technical basis
for the findings seems unlikely. From the aforementioned
chemical carcinogen-associated possible carcinogenesis, the
narrow spectrum of mutations might well reflect the special
characteristics of cholangiocarcinogenesis in Japan. With
regard to the genesis without associated Ki-ras mutation, we
and another Japanese group previously reported that chronic
mechanical irritation by gall stones, parasites or virus
infection are possible causal factors from investigation of
ICC cases (Tsuda et al., 1993; Ohashi et al., 1995). However,
a separate pathogenesis might be involved with ECC or
GBC, and more detailed studies including investigations in
animal models are necessary to elucidate this point.
This is the first assessment, to the best our knowledge, of
the proliferation activity of BTCs in relation to Ki-ras
mutations. The present results indicate significantly higher
proliferation in mutation-positive cases than in mutation-
negative ones. This may suggest a greater propensity of Ki-
ras-mutated cases to progress to biological malignancy.
Mutations in the ras gene induce drastic increase in the
active form of ras protein, in the GTP-bound state, which
locks signal transduction in the 'on' position and possibly
leads cells into DNA synthesis (Trahey et al., 1987). From
this point of view, harbouring a Ki-ras mutation must
represent an advantage in terms of growth and progression.
Finally, the success of mutated Ki-ras-targeted experi-
mental therapy is noteworthy in consideration of contriving
therapeutic strategies for BTC in the future (Krzyzoiak et al.,
1992; Sumi et al., 1992; Shirasawa et al., 1993). Considerable
anti-proliferative or anti-cancer effects have been exhibited on
cultured cell lines and refinement of this approach shouldKi-ra --I -m Ii bwy t cuckmas
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contribute to cure of Ki-ras mutation-harbouring cancer
patients. According to the frequencies of mutations in BTCs
revealed by the present study, patients with GBCs and distal
ECCs should be considered as good candidates for Ki-ras
gene-targeted therapy.
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